HCPCS codes / M / M1412
M1412
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
- Code type
- HCPCS Level II
- Coverage
- Carrier judgment
- BETOS category
- Z2
- Pricing indicator
- 00
- Effective date
- 20250101
Verify before billing. Confirm against current official CMS HCPCS files and your payer's rules before clinical or claims use.